Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Abiraterone Acetate

FDA-approved product (tablet, oral), marketed as Abiraterone Acetate, Yonsa, Zytiga.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Abiraterone Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Metastatic prostate cancer
  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other hormone antagonists and related agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli34.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis27.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Abiraterone Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Abiraterone Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Abiraterone Post Ketoconazole for Prostate Cancer

    NCT01199146 · start 2010-09-10

    Registered record
    Registry ID
    NCT01199146
    Conditions
    Prostate Cancer
    Interventions
    Abiraterone acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-09-10
    Completion
    2016-03-14
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionAbiraterone acetate
    PhasePhase 2
    Registry statusCompleted

  • Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer

    NCT01186484 · start 2010-06-01

    Registered record
    Registry ID
    NCT01186484
    Conditions
    Prostatic Neoplasms
    Interventions
    JNJ-212082
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-06-01
    Completion
    2014-10-02
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms
    InterventionJNJ-212082
    PhasePhase 1
    Registry statusCompleted

  • A Study to Determine the Effect of Food on the Pharmacokinetics of Abiraterone Acetate in Healthy Male Patients

    NCT01798628 · start 2009-09

    Registered record
    Registry ID
    NCT01798628
    Conditions
    Healthy Volunteers
    Interventions
    Treatment A: abiraterone acetate; Treatment B: abiraterone acetate; Treatment C: abiraterone acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-09
    Completion
    2009-10
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionTreatment A: abiraterone acetate; Treatment B: abiraterone acetate; Treatment C: abiraterone acetate
    PhasePhase 1
    Registry statusCompleted

  • A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

    NCT00910754 · start 2009-05

    Registered record
    Registry ID
    NCT00910754
    Conditions
    Prostate Neoplasms
    Interventions
    Abiraterone acetate; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-05
    Completion
    2012-05
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Neoplasms
    InterventionAbiraterone acetate; Prednisone
    PhasePhase 1
    Registry statusCompleted

  • Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

    NCT05401214

    Registered record
    Registry ID
    NCT05401214
    Conditions
    Metastatic Castration-resistant Prostate Cancer
    Interventions
    Niraparib plus Abiraterone Acetate (Nira/AA) combination; Prednisone/Prednisolone
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Approved for marketing
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-resistant Prostate Cancer
    InterventionNiraparib plus Abiraterone Acetate (Nira/AA) combination; Prednisone/Prednisolone
    PhaseNot recorded
    Registry statusApproved for marketing